Clinical-stage biotechnology company developing oncolytic immunotherapies for cancer.
Replimune Group, Inc. is a pioneering biotechnology company dedicated to advancing oncolytic immuno-gene therapies for the treatment of cancer. Established in 2015 and based in Woburn, Massachusetts, the company harnesses its proprietary Immunotherapy platform to design and develop innovative product candidates aimed at activating the immune system's response against cancerous cells.
At the forefront of its pipeline is RP1, a selectively replicating version of herpes simplex virus 1. RP1 is currently undergoing Phase I/II clinical trials targeting a broad spectrum of solid tumors, with additional Phase II trials focusing specifically on patients diagnosed with cutaneous squamous cell carcinoma.
In addition to RP1, Replimune Group is advancing RP2 through Phase I clinical trials. RP2 represents an anti-CTLA-4 antibody-like protein designed to counteract the immune response inhibition typically induced by CTLA-4, thereby potentially enhancing the body's ability to combat cancer.
Furthermore, the company is developing RP3, which is also in Phase I clinical trials. RP3 aims to express immune-activating proteins that stimulate T cells, further bolstering the immune response against cancerous cells. Replimune Group, Inc. continues to innovate in the field of immuno-gene therapies, driven by a commitment to pioneering treatments that could redefine the landscape of cancer care.